Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer's Record-Breaking $2.3 Bil. Settlement With U.S. Attorney Imposes New Restrictions on Corporate Behavior

Executive Summary

Pfizer's $2.3 billion settlement with the U.S. Department of Justice is unprecedented in size and scope, resolving allegations of off-label marketing of four drugs and kickbacks to health care providers involving nine other drugs. Moreover, the deal includes the largest criminal fine ever imposed by the U.S. government in any matter

You may also be interested in...



Pfizer Agrees To Oversight Of Charitable Assistance Programs In DOJ Settlement

Second pharma charity kickback settlement in six months resolves claims Pfizer used charity to pay Medicare patient copays for three drugs.

Wyeth Rapamune Off-Label Marketing Settlement Will Not Alter Pfizer’s CIA

Pfizer subsidiary to pay $490.9 million to resolve criminal and civil liability for marketing its immunosuppressive for unapproved uses; actions predate Pfizer’s 2009 corporate integrity agreement.

Health Care Fraud Tipsters May Get Bigger Reward; Novartis Kickback Complaint Prompts CIA Review

HHS proposes to increase the potential reward for information leading to recovery of Medicare funds from $1,000 to $9.9 million; OIG is reviewing Novartis corporate integrity agreement compliance after government alleges company paid Myfortic kickbacks to pharmacies.

Related Content

Topics

UsernamePublicRestriction

Register

PS051461

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel